Akiram's AKIR001 Shows No Dose-Limiting Toxicity in 8 Patients
Uppsala – October 13, 2026 -- Akiram Therapeutics reported no dose-limiting toxicities among the eight patients treated so far with its lead radiopharmaceutical candidate 177Lu-AKIR001 in a Phase I trial, with treatment-related adverse events limited to grade 1-2.
The Swedish clinical-stage biotech will present the first clinical data at the EANM 2026 Congress in Vienna, October 17-21. The abstract was selected as a Top Rated Oral Presentation (TROP).
Sustained tumor retention supports continued dose escalation
The first-in-human study is evaluating 177Lu-AKIR001 in patients with irresectable or metastatic CD44v6-positive solid tumors who have no remaining standard treatment options. At data cut-off, eight patients had been treated, and four of them received repeat treatment after the first administration.